

New Biopsy Tool Predicts Prostate Tumor Spread

BY FRAN LOWRY
Orlando Bureau

ORLANDO — A new tool can predict the risk of tumor progression or death within 5 years for men with prostate cancer, the physician who developed the technique said at a symposium on prostate cancer sponsored by the American Society of Clinical Oncology.

In the model, high levels of androgen receptor, as measured by quantitative immunofluorescence staining in prostate tissue from men who had radical prostatectomy, correlated with a shortened time to clinical failure, said Dr. Michael J. Donovan of Aureon Laboratories Inc., Yonkers, N.Y.

"This tool is the first to measure the amount of androgen receptor protein pre-

sent in a single cancer cell. Androgen receptors are proteins present in normal as well as cancerous prostate cells, and play a role in prostate cancer progression by acting as binding sites for the androgens that fuel cancer growth," Dr. Donovan said at the symposium, cosponsored by the Society of Urologic Oncology and the American Society for Therapeutic Radiology and Oncology.

When applied to tissue samples from 881 men who had surgery at Memorial

Sloan-Kettering Cancer Center, New York, between 1985 and 2003, the tool was 84% accurate in predicting the time to clinical progression and spread of prostate cancer within 5 years.

It also showed that the risk of cancer progressing increased as the level of androgen receptors in a single prostate cancer cell increased.

The predictive tool incorporates the patient's clinical features, including biopsy and prostatectomy Gleason grade, lymph

node status, and seminal vesicle invasion.

A sample of the patient's prostate tissue is stained with a multiplex immunofluorescent assay to highlight androgen receptor antibodies and other antibodies, which are then analyzed with a special software application to predict the likelihood of clinical failure within 5 years. A relative risk number is also generated, Dr. Donovan said.

"A patient could have a 30% or 40% risk of having a clinical failure within 5 years,

Early Prostate Cancer Detection Hits a Plateau

ORLANDO — For the first time since the advent of widespread prostate-specific antigen screening, identification of early-stage prostate cancers has begun to level off, Dr. Eric A. Klein said at a symposium on prostate cancer sponsored by the American Society of Clinical Oncology.

An analysis of prostate cancer detection trends among 3,364 men treated with prostatectomy at the Cleveland Clinic between 1987 and 2005 showed that the percentage of tumors that had spread beyond the prostate at the time of surgery decreased from 79% to 25%. However, this trend has now plateaued, said Dr. Klein, professor of surgery and head of urologic oncology at the Cleveland Clinic's Glickman Urological Institute. Since 1998, the percentage of tumors found to have spread beyond the prostate ranged from 25% to 36%.

Before prostate-specific antigen (PSA) testing, half of men initially diagnosed with prostate cancer had stage C or D disease—incurable cancer outside the prostate. Just 5 years after PSA screening was introduced, 95% of newly diagnosed prostate cancer was being picked up at a curable stage, Dr. Klein said at the symposium, cosponsored by the Society of Urologic Oncology and the American Society for Therapeutic Radiology and Oncology.

"The increase in prostate cancer survival rates that we have seen over the past 20 years is no doubt due to widespread PSA testing that has allowed us to detect cancers in their early, more curable stage," he said. But now, the rise in rates of cure because of the likelihood of having an organ-confined disease has ended.

"We're not going to see gains in cure rates beyond what we've already achieved simply based on PSA screening. Additional increments in cure to 100% will require [truly] new therapeutic advances both in surgery and radiation therapy, and, I believe, in molecular agents," Dr. Klein said.

—Fran Lowry

"★★★★★" — Doody's
Book Review Service

CECIL TEXTBOOK OF MEDICINE GOLDEN EDITION

NEW Edition

Includes image bank CD-ROM!

CECIL
Trust our knowledge to take you further.

and depending upon the features that generated the model, he could have a relative risk of 1.2 to 2 times the likelihood of having clinical failure within a 5-year period," he said.

The model can also analyze tissue obtained from needle biopsies, and Dr. Donovan hopes to be able to apply it in an active surveillance cohort of patients. He and his coinvestigators are in the final stages of building a predictive model that will use biopsy tissue from patients after prostatectomy to predict outcome in two groups in the United States and Europe.

"Conceptually, this is very exciting.

Will the pathology tell us what the likelihood of cure is, or is there something that the pathologist can't see that suggests that the cure rate might be lower than we thought, and does the patient in fact need additional, adjuvant therapy?" asked Dr. Eric A. Klein, professor of surgery and head of urologic oncology at the Glickman Urological Institute of the Cleveland Clinic Foundation, who chaired the press conference where Dr. Donovan presented his new model.

Dr. Donovan disclosed that he also is employed by Aureon Biosciences and that he owns stock in that company and Aureon Laboratories. ■





Image analysis of prostate tissue is used to quantify the locations of androgen receptor protein and other proteins within a cell. Here, the androgen receptor is red, CK18 is green, nuclei are blue, and alpha-methylacyl-coenzyme A racemase (AMACR) is orange.

AUREON LABORATORIES

DETROL LA is the #1 prescribed brand for OAB*— with BIG REDUCTIONS in OAB symptoms^{1,2}

REDUCE SEVERE URGENCY INCONTINENCE (UI) EPISODES



Van Kerrebroeck et al. *Urology*. 2001;57:414-421.¹
A 12-week, placebo-controlled study.
See full study description on next page.

Landis et al. *J Urol*. 2004;171:752-756.²
A post hoc subgroup analysis of the Van Kerrebroeck study.
See full study description on next page.

DETROLLA is indicated for the treatment of overactive bladder with symptoms of urge incontinence, urgency, and frequency. DETROL LA is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma and in patients who have demonstrated hypersensitivity to the drug or its ingredients. DETROL LA capsules should be used with caution in patients with clinically significant bladder outflow obstruction, gastrointestinal obstructive disorders, controlled narrow-angle glaucoma, and significantly reduced hepatic or renal function. Dry mouth was the most frequently reported adverse event (DETROLLA 23% vs placebo 8%); others (≥4%) included headache (DETROLLA 6% vs placebo 4%), constipation (DETROLLA 6% vs placebo 4%), and abdominal pain (DETROLLA 4% vs placebo 2%).

* Source: IMS Health, NPA data, based on total US prescriptions of antimuscarinics for OAB from October 2001 to November 2006.

† Source: IMS Midas Global Sales Audit, Verispan longitudinal data, based on total prescriptions of DETROL and DETROL LA for OAB from April 1998 to October 2006.

86 million prescriptions[†]  once-daily **Detrol LA**
tolterodine tartrate
extended release capsules

Improved Control. Less Bother.™

Please see important product information on next page.